Literature DB >> 25981138

Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.

D M Adcock1, R Gosselin2.   

Abstract

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have recently been introduced and may have advantages over vitamin K antagonists such as warfarin. This review describes briefly the clinical utility and mechanism of action of these agents. Detailed information is provided on effect of these agents on routine assays including the APTT and PT as well as their impact on specialty laboratory assays. Also included are the use of drug specific assays and a discussion of alternative methods to determine relative drug concentration, such as evaluating drug calibrators in APTT and PT assays and using heparin calibrated anti-Xa assays to measure direct Xa inhibitors.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DOAC; Direct Xa inhibitor; Direct thrombin inhibitor; Laboratory assays; Oral anticoagulant

Mesh:

Substances:

Year:  2015        PMID: 25981138     DOI: 10.1016/j.thromres.2015.05.001

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  30 in total

1.  The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

Authors:  L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich
Journal:  J Interv Card Electrophysiol       Date:  2017-07-22       Impact factor: 1.900

2.  Pharmacogenetics and Personalized Medicine in Hematology.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-07-04       Impact factor: 0.900

3.  Safety of The Direct Oral Anticoagulant Edoxaban for Atrial Fibrillation After Cardiac Surgery: Pilot Study.

Authors:  Akira Sezai; Shunji Osaka; Hiroko Yaoita; Munehito Arimoto; Hiroaki Hata; Motomi Shiono
Journal:  J Atr Fibrillation       Date:  2016-10-31

4.  Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.

Authors:  Nishank Jain; Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-25       Impact factor: 8.237

Review 5.  Use of direct oral anticoagulants in daily practice.

Authors:  Feras Almarshad; Ali Alaklabi; Ebtisam Bakhsh; Aslam Pathan; Mosaad Almegren
Journal:  Am J Blood Res       Date:  2018-12-10

Review 6.  Prevention and Treatment of Bleeding with Direct Oral Anticoagulants.

Authors:  R Monroe Crawley; Rachel L Anderson
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

7.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 8.  Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.

Authors:  Shannon W Finks; Toby C Trujillo; Paul P Dobesh
Journal:  Ann Pharmacother       Date:  2016-02-25       Impact factor: 3.154

Review 9.  Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions.

Authors:  Eveline T Engelen; Roger Eg Schutgens; Evelien P Mauser-Bunschoten; Robert Jj van Es; Karin Pm van Galen
Journal:  Cochrane Database Syst Rev       Date:  2018-07-02

Review 10.  Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians.

Authors:  W Frank Peacock; Zubaid Rafique; Adam J Singer
Journal:  Emerg Med Int       Date:  2016-05-16       Impact factor: 1.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.